Research Reports

Synthetic Oxytocic Pharmaceuticals will Amass Nearly US$ 207.80 Million Revenues by 2031-end

Published by Uma Rajagopal

Posted on February 2, 2022

5 min read

· Last updated: January 28, 2026

Add as preferred source on Google
Graph illustrating the growth trends in the global emulsion explosive market - Global Banking & Finance Review
A detailed graph showcasing the projected double-digit CAGR in the global emulsion explosive market from 2021 to 2028. This image supports the report's insights on market dynamics and growth opportunities.

Synthetic Oxytocic Pharmaceuticals to Reach $207.80 Million by 2031

 

Though synthetic oxytocin is chemically equivalent to naturally-occurring oxytocin, their pharmaceutical functions for aiding women in labour are quite distinctive. Medical professionals from around the world will continue to recommend synthetic-based oxytocic pharmaceuticals over natural since oxytocic pharmaceuticals originating from synthetic sources can boost the momentum of decelerated labour by IV administration. More than 90% of the global market revenues for oxytocic pharmaceuticals will be harvested from the sales of oxytocic pharmaceuticals originating from synthetic sources. By the end of 2031, an estimated US$ 207.80 million revenues will be emanated from the global sales of synthetic oxytocic pharmaceuticals.

Future Market Insights’ published report on the global oxytocic pharmaceuticals market estimates that the market, which is presently valued at US$ 62.2 million, will expand at an impressive 7.74% CAGR to reach US$ 207.80 million value by 2031-end. In the report, titled “Oxytocic Pharmaceuticals Market: Global Industry Analysis & Opportunity Assessment, 2021-2031,”

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1445

Future Market Insights projects that the global market for oxytocic pharmaceuticals will remain highly fragmented due to higher prevalence of local players as opposed to multinationals and conglomerates. Nevertheless, global pharmaceutical industry leaders such as Pfizer Inc., Novartis AG, Baxter Healthcare Corporation, and Teva Pharmaceutical Industries Ltd. are also partaking in the global oxytocic pharmaceuticals market. Other leading manufacturers of oxytocic pharmaceuticals include Biofutura Pharma SpA, Ferring BV, and Fresenius Kabi AG.

Global Oxytocic Pharmaceuticals Market: Regional Analysis

The need for oxytocic pharmaceuticals in the world will always remain contingent to the rise in pregnancy incidences and birth rate. Various parts of the world exhibit diverse birth rate, which incidentally drives the growth of their oxytocic pharmaceuticals market, accordingly. In North America, oxytocic pharmaceuticals are majorly used for postpartum haemorrhage, which is one of the most-prominent indication among labouring women in the US and Canada.

However, China is expected to remain the largest market for oxytocic pharmaceuticals in the world. Considering the country’s exploding birth rate, China’s oxytocic pharmaceuticals market will be valued over US$ 55 million by 2031-end, expanding at 9.8% CAGR. In 2016, Japan’s oxytocic pharmaceuticals revenues amounted to an estimated US$ 1.7 million, while the oxytocic pharmaceuticals market in Asia-Pacific excluding Japan & China (APEJC) region has been estimated to account for nearly 20% of global revenues.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-1445

Global Oxytocic Pharmaceuticals Market: Research Highlights

  • Licensing agreements for development of newer oxytocic pharmaceuticals is rampantly boosting the global market revenues, profiting local players as well as industry leaders.
  • Surging prevalence of labour induction procedures for child births will continue promoting the use of oxytocic pharmaceuticals throughout the forecast period.
  • The global oxytocic pharmaceuticals revenues, however, are projected to witness an inhibited growth on the account of rising preference to alternative drugs such as magnesium sulphate and misoprostol.
  • India’s contribution to the APEJC oxytocic pharmaceuticals market is predicted to reach nearly 60% by the end of 2031.
  • More than 22,000 thousand units of oxytocic pharmaceuticals will be sold globally for treating labour arrest over the forecast period.
  • Hospitals will remain the largest end-user of oxytocic pharmaceuticals in the world, revenues from which will expand beyond 12% CAGR.
  • A majority of medical professionals in the world will recommend intravenous administration of oxytocic pharmaceuticals, accounting for more than two-third of global market revenues by the end of 2031.

 

For critical insights on this market, request to ask an expert here @ https://www.futuremarketinsights.com/askus/rep-gb-1445

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

Explore FMI’s Extensive Coverage on Healthcare Domain 

Lung Cancer Surgery Market The global Lung Cancer Surgery Market was valued at US$ 1.23 Bn in 2021 and is expected to reach US$ 1.98 Bn by 2029

Multiplex Biomarker Imaging Market The global Multiplex Biomarker Imaging Market was valued at US$ 422.1 Mn in 2021 and is expected to reach US$ 1,041.7 Mn by 2029

Atopic Dermatitis Treatment Market The Global Atopic Dermatitis Treatment Market was valued at US$ 5.2 Bn in 2021 and is expected to reach US$ 7.6 Bn by 2029

 

About Future Market Insights (FMI) 

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reportsand industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. 

 

Contact: 

Future Market Insights, 

1602-6 Jumeirah Bay X2 Tower, 

Plot No: JLT-PH2-X2A, 

Jumeirah Lakes Towers, Dubai, 

United Arab Emirates 

For Sales Enquiries: sales@futuremarketinsights.com 

For Media Enquiries: press@futuremarketinsights.com

Website: https://www.futuremarketinsights.com/ 

Report: https://www.futuremarketinsights.com/reports/oxytocic-pharmaceuticals-market
Press Release Source https://www.futuremarketinsights.com/press-release/oxytocic-pharmaceuticals-market

Key Takeaways

  • Synthetic oxytocic pharmaceuticals are preferred over natural ones.
  • Global market to reach $207.80 million by 2031.
  • China leads the market with a high growth rate.
  • Hospitals are the largest end-users.
  • Licensing agreements boost market revenues.

Frequently Asked Questions

What is the main topic?
The article discusses the growth of the synthetic oxytocic pharmaceuticals market, projected to reach $207.80 million by 2031.
Why are synthetic oxytocic pharmaceuticals preferred?
They are preferred due to their ability to boost the momentum of decelerated labour through IV administration.
Which region is leading the market?
China is expected to be the largest market due to its high birth rate and demand for oxytocic pharmaceuticals.

Related Articles

More from Research Reports

Explore more articles in the Research Reports category